biomodal Files Patent Infringement Lawsuit Against New England Biolabs
July 02 2024 - 8:30AM
Business Wire
biomodal, an omics-based life sciences technology and analytics
company, today announced it has filed a lawsuit against New England
Biolabs (“NEB”) in the United States District Court for the
District of Massachusetts. The lawsuit seeks damages and a court
order to stop NEB from making, using, selling, or offering for sale
all NEBNext® Enzymatic 5hmC-seq products, and NEBNext® Enzymatic
Methyl-seq products in clinical markets, or otherwise infringing on
patents exclusively licensed by biomodal from Boston Children’s
Hospital through Children’s Medical Center Corporation (“CMCC”), as
outlined in the complaint.
biomodal is the exclusive licensee to patents invented by
Professor Anjana Rao et al., relating to inter alia uses of ten
eleven translocation (TET) enzymes in methods to detect methylation
and/or hydroxymethylation, as well as all uses of DNA
beta-glucosyltransferase (BGT) enzymes in methods to detect
methylation and/or hydroxymethylation. The 8 patents asserted are
U.S. Patent Nos. 10,337,053 B2; 10,443,091 B2; 10,533,213 B2;
10,731,204 B2; 10,774,373 B2; 10,767,216 B2; 11,072,818 B2; and
11,208,683 B2.
biomodal utilizes the patented ’Rao’ technology in its duet
multiomics solution evoC, a 6-base genome technology that combines
genetic and epigenetic information to provide
single-base-resolution sequencing data that reveals standard
four-base sequencing (A, C, G, and T) and distinguishes between
5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), on the
same DNA molecule. The Rao technologies also underlie biomodal’s
duet multiomics solution +modC, which delivers genetic and
epigenetic methylation at single base resolution to provide a
5-base genome.
"biomodal has made significant investments to bring our novel
duet platform to market through both our duet evoC and +modC
offerings. Built on the original ideas of our Scientific Advisory
Board member, Anjana Rao, and her collaborators, we have integrated
assay and software into a comprehensive solution which enables
unparalleled insight into biological systems through the dynamic
interplay of genetics and epigenetics," said Peter Fromen, CEO of
biomodal. "As a company with innovation at its core, we strongly
believe in the role of intellectual property in our industry, and
we will act vigorously to protect our IP rights and our customers’
ability to apply differentiated solutions that deliver
best-in-class results."
biomodal’s growing patent portfolio currently includes more than
25 U.S. and over 40 internationally issued patents, with more than
75 patent applications pending worldwide.
About biomodal
biomodal is an omics-based life-sciences technology and
analytics company delivering products that bring the dynamism of
our ever-changing biology into focus. Our duet multiomics solutions
enable more epigenetic information from a single, low input DNA
sample without complex, resource intensive bioinformatics or harsh
chemical treatment. Our single-base-resolution, resolved sequencing
approach unlocks the combinatorial power of genetic and epigenetic
information in one workflow, elucidating greater biological insight
within the fields of cancer, neurodegenerative disease, and
ageing.
Please visit biomodal.com or follow the Company on LinkedIn at
linkedin.com/company/biomodal.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240702115451/en/
Donna McDade Walker, PhD VP, Global Marketing & Product
Management donna.mcdadewalker@biomodal.com